Syphilis Diagnosis: RPR, VDRL, FTA-ABS, and TPPA

Syphilis cannot be diagnosed from symptoms alone — too many conditions look similar. Diagnosis depends on blood tests, and the testing system is a two-step process using two entirely different types of antibody. Understanding what each test measures, why both are needed, and what the results actually mean helps you make sense of your lab report and have an informed conversation with your doctor.

Why Syphilis Requires Two Types of Blood Test
Non-Treponemal Tests: RPR and VDRL
Treponemal Tests: FTA-ABS, TPPA, and EIAs
The Traditional (Forward) Testing Algorithm
The Reverse Sequence Screening Algorithm
The Prozone Phenomenon: When a Positive Looks Negative
Dark-Field Microscopy for Active Chancres
CSF Analysis for Neurosyphilis
False Positives and Their Causes
Rapid Point-of-Care Tests
Key Research Papers
Featured Videos

1. Why Syphilis Requires Two Types of Blood Test

Treponema pallidum cannot be grown in laboratory culture — it is one of very few major bacterial pathogens that has never been successfully cultured on artificial media. This means the workhorse of infectious disease diagnosis (isolating the organism and confirming it) is simply not available. All diagnosis depends on detecting the immune response to the infection.

The immune response to syphilis generates two distinct types of antibodies, each detected by a different class of test:

Non-treponemal antibodies are not actually directed at the spirochete itself. They are directed at cardiolipin, a lipid released from damaged cells (both syphilitic lesions and inflamed host cells) during infection. These antibodies fluctuate with disease activity and decrease after treatment — making them ideal for monitoring treatment response. But because cardiolipin damage occurs in other conditions too, these tests generate false positives.
Treponemal antibodies are directed specifically at T. pallidum proteins. They are highly specific for true syphilis infection but remain positive for life even after successful treatment. So they cannot monitor treatment response, but they confirm true infection.

The two-test algorithm combines these strengths: a non-treponemal test (RPR or VDRL) screens and monitors; a treponemal test (FTA-ABS, TPPA, or EIA) confirms.

2. Non-Treponemal Tests: RPR and VDRL

The two non-treponemal tests in common use are the RPR (Rapid Plasma Reagin) and the VDRL (Venereal Disease Research Laboratory) test. Both detect antibodies to a cardiolipin-cholesterol-lecithin antigen. The tests differ slightly in methodology (RPR uses a carbon particle antigen visible to the naked eye; VDRL is read under a microscope) but are clinically equivalent.

Key features of RPR/VDRL:

Quantitative: Results are reported as a titer — a dilution factor indicating the concentration of antibody. Common titers: 1:1, 1:2, 1:4, 1:8, 1:16, 1:32, 1:64, 1:128. High titers (1:32 or above) indicate active, untreated infection. Very high titers sometimes indicate secondary syphilis.
Monitors treatment response: A successful treatment response is defined as a fourfold (two-dilution) drop in titer within 6 to 12 months. For example, a titer falling from 1:32 to 1:8 confirms adequate therapy. Failure to achieve this decline suggests treatment failure or reinfection.
Sensitive but not specific: Both tests are highly sensitive for secondary and early latent syphilis (close to 100%). Sensitivity is lower for primary syphilis (approximately 70–85%) in the very early days after chancre appearance, and lower for late latent and tertiary syphilis (70–80%).
False positives: Occur in autoimmune diseases, pregnancy, other infections (HIV, malaria, tuberculosis, EBV), intravenous drug use, and aging. This is why a positive RPR always requires treponemal confirmation.

3. Treponemal Tests: FTA-ABS, TPPA, and EIAs

The confirmatory treponemal tests detect antibodies specifically targeting proteins of T. pallidum. Several tests are available:

FTA-ABS (Fluorescent Treponemal Antibody Absorbed): The historical gold standard. The patient's serum is first "absorbed" with non-pathogenic treponemal antigens to remove cross-reactive antibodies, then applied to a slide containing fixed T. pallidum organisms, followed by a fluorescent-labeled anti-human antibody. A positive result shows fluorescent spirochetes under the microscope. Labor-intensive and requires fluorescence microscopy.

TPPA (T. pallidum Particle Agglutination) and TP-PA: A simpler agglutination test in which gelatin particles coated with treponemal antigens visibly clump in the presence of positive serum. Easier to perform than FTA-ABS and widely used.

Treponemal EIAs (enzyme immunoassays) and chemiluminescence immunoassays (CIAs): Automated platforms that have largely replaced FTA-ABS and TPPA in high-volume laboratories because they can process hundreds of samples per hour. These are now the most common treponemal tests in US clinical labs and are the basis of the reverse sequence algorithm.

Key features of all treponemal tests:

Remain positive for life. Once a person has been infected with syphilis and tests positive on a treponemal test, this test remains positive indefinitely — even decades after successful treatment and cure. This is the most important limitation: treponemal tests cannot distinguish past treated infection from current active infection.
Qualitative results only. Unlike RPR/VDRL, treponemal tests report positive or negative, not a titer. They cannot be used to monitor treatment.
High sensitivity and specificity. True false positives are rare but occur in Lyme disease, some autoimmune conditions, and occasionally other spirochetal infections.

4. The Traditional (Forward) Testing Algorithm

The traditional (and still widely used) approach to syphilis testing is:

Screen with non-treponemal test (RPR or VDRL)
If positive, confirm with treponemal test (FTA-ABS, TPPA, or EIA)
If both positive, diagnose syphilis and determine stage from clinical history
If non-treponemal positive but treponemal negative, consider biological false positive; no treatment indicated

This algorithm works well in most settings. Its main limitation is slightly lower sensitivity for very early primary syphilis, when RPR can be negative in the first one to two weeks after chancre appearance (antibodies have not yet developed to detectable levels). A person with a classic chancre and a negative RPR should have the test repeated in two to four weeks.

5. The Reverse Sequence Screening Algorithm

High-volume laboratories increasingly use a reversed algorithm:

Screen with automated treponemal EIA or CIA (high throughput, no technician interpretation needed)
If treponemal EIA positive, test with non-treponemal RPR or VDRL
Interpret results: if both positive → current syphilis; if treponemal positive + non-treponemal negative → ambiguous (past treated syphilis vs. false-positive treponemal vs. very early primary)
For treponemal+/non-treponemal- cases: add second treponemal test (TP-PA) for resolution

This algorithm is more sensitive for very early primary syphilis (treponemal tests can be positive before RPR becomes positive). But it generates more cases of diagnostic uncertainty: a person treated for syphilis 10 years ago has a positive treponemal EIA and a negative RPR, which can confuse both clinicians and patients. The second treponemal test (TP-PA) helps confirm true seropositivity, but clinical history remains essential.

6. The Prozone Phenomenon: When a Positive Looks Negative

The prozone phenomenon is an important diagnostic pitfall in syphilis testing. In secondary syphilis, antibody concentrations can be so high that the non-treponemal test is paradoxically reported as negative at the standard test dilution — because an excess of antibody saturates the antigen and prevents agglutination.

Think of it like trying to make a handshake happen in a crowd: if there are too many people trying to shake hands at once, no hands actually connect. The antibody is present and real, but the assay reads negative.

Clinically, suspect the prozone phenomenon in a patient with classic secondary syphilis symptoms (the rash, palms and soles involvement) and a negative RPR. The solution is to request that the laboratory dilute the sample before testing — or to order a treponemal test directly. At higher dilutions, the antibody excess resolves and the test becomes positive. The prozone effect has been reported in up to 2% of secondary syphilis cases.

7. Dark-Field Microscopy for Active Chancres

When a primary chancre or secondary-stage lesion is present, dark-field microscopy of material collected directly from the lesion can confirm the diagnosis immediately, without waiting for blood tests to become positive.

The procedure: a small amount of fluid from the base of the chancre (or from a condyloma lata) is placed on a glass slide and examined under a dark-field microscope. This specialized microscope illuminates the specimen from the side, making the thin, moving spirochetes visible against a dark background as bright, corkscrew-shaped organisms with characteristic motility (a gentle bending and rotating motion).

Dark-field microscopy is the only syphilis diagnostic modality that does not require serologic antibody development — it detects the organism directly. This makes it valuable in the very early days of primary syphilis when RPR may still be negative. However, it requires a skilled microscopist, immediate examination (spirochetes die quickly on the slide), and has largely been replaced by PCR in modern laboratories.

Important exception: Dark-field microscopy should not be used on oral lesions because the mouth contains non-pathogenic treponemes that are morphologically identical to T. pallidum under the microscope, leading to false-positive results. For oral lesions, PCR is the appropriate direct-detection method.

8. CSF Analysis for Neurosyphilis

Lumbar puncture (spinal tap) to analyze cerebrospinal fluid is needed when neurosyphilis is suspected. The CSF-VDRL is the specific syphilis test performed on CSF:

Sensitivity: Low (~30–70%). A negative CSF-VDRL does not exclude neurosyphilis.
Specificity: Very high. When positive, it is near-diagnostic for neurosyphilis (contamination with blood from a traumatic tap is a rare confound).
Supporting findings: CSF protein elevation (>45 mg/dL) and pleocytosis (>5 white blood cells/μL) indicate meningeal inflammation consistent with neurosyphilis.
CSF-FTA-ABS: More sensitive than CSF-VDRL but less specific; a negative result can help rule out neurosyphilis.

Neurosyphilis should be considered (and lumbar puncture performed) in any patient with syphilis who has: neurologic symptoms of any kind, ophthalmologic or hearing abnormalities, tertiary syphilis, treatment failure, or HIV co-infection with late latent or unknown-duration syphilis.

9. False Positives and Their Causes

A positive non-treponemal test (RPR or VDRL) that is not confirmed by a treponemal test is called a biological false positive (BFP). BFPs occur because the cardiolipin antigen used in these tests is a normal cell membrane component released by damaged or inflamed cells of any kind, not only those damaged by syphilis. Common causes of BFPs include:

Pregnancy: Low-titer BFPs are common; all pregnant women should have treponemal confirmation
Autoimmune diseases: Particularly systemic lupus erythematosus (SLE) and antiphospholipid syndrome; the antiphospholipid antibodies cross-react with cardiolipin
Other infections: HIV, tuberculosis, malaria, Epstein-Barr virus (mononucleosis), mycoplasma pneumonia
Intravenous drug use: Mechanism unclear, possibly chronic immune activation
Advanced age: Low-titer BFPs become more common after age 70
Recent immunization: Short-lived BFPs after some vaccines

The titer is a useful guide: true syphilis infection typically generates titers of 1:8 or higher during active infection. A BFP is usually at a low titer (1:1 to 1:4). However, this is a rule of thumb, not an absolute — lupus can generate high titers, and primary syphilis may have low titers early. Treponemal confirmation is always required.

10. Rapid Point-of-Care Tests

Point-of-care (POC) rapid syphilis tests are approved by the WHO and used globally, particularly in low-resource settings and antenatal clinics where laboratory infrastructure is limited. They require only a finger-stick blood sample and return a result in 15 to 20 minutes without laboratory equipment.

Rapid tests detect treponemal antibodies (making them specific for T. pallidum and resistant to the common causes of BFP). Their key characteristics:

Sensitivity: Comparable to laboratory treponemal EIA in most studies (>85%).
Specificity: High (>95% in most evaluations).
Results positive for life: Like all treponemal tests, they remain positive after successful treatment. They cannot determine whether infection is current or past.
Value in pregnancy: The ability to test and treat a pregnant woman in a single visit dramatically reduces congenital syphilis when used in antenatal care settings.

Dual rapid tests (detecting both syphilis and HIV from a single finger-stick) are now available and are being deployed in high-burden settings.

Key Research Papers

Workowski KA, Bachmann LH, Chan PA, et al. Sexually transmitted infections treatment guidelines, 2021. MMWR Recomm Rep. 2021;70(4):1–187. PMID 34292926
Ratnam S. The laboratory diagnosis of syphilis. Can J Infect Dis Med Microbiol. 2005;16(1):45–51. PMID 18159528
Binnicker MJ, Jespersen DJ, Rollins LO. Treponema-specific tests for serodiagnosis of syphilis: comparative evaluation of seven assays. J Clin Microbiol. 2011;49(4):1313–1317. PMID 21191058
Marra CM, Maxwell CL, Smith SL, et al. Cerebrospinal fluid abnormalities in patients with syphilis: association with clinical and laboratory features. J Infect Dis. 2004;189(3):369–376. PMID 14745693
Jafari Y, Peeling RW, Shivkumar S, Claessens C, Joseph L, Pai NP. Are Treponema pallidum specific rapid and point-of-care tests for syphilis accurate enough for screening in resource limited settings? Evidence from a meta-analysis. PLoS One. 2013;8(2):e57709. PMID 23469044
Peeling RW, Mabey D. Point-of-care tests for diagnosing infections in the developing world. Clin Microbiol Infect. 2010;16(8):1062–1069. PMID 20670292
Park IU, Chow JM, Bolan G, Stanley M, Shieh J, Schachter J. Screening for syphilis with the treponemal immunoassay: analysis of discordant serology results and implications for clinical management. J Infect Dis. 2011;204(9):1297–1304. PMID 21933875
Mishra S, Walmsley SL, Loutfy MR, et al. Otosyphilis in HIV-coinfected individuals: a case series from Toronto, Canada. AIDS Patient Care STDS. 2008;22(3):213–219. PMID 18335006
Larsen SA, Steiner BM, Rudolph AH. Laboratory diagnosis and interpretation of tests for syphilis. Clin Microbiol Rev. 1995;8(1):1–21. PMID 7704895
Golden MR, Marra CM, Holmes KK. Update on syphilis: resurgence of an old problem. JAMA. 2003;290(11):1510–1514. PMID 13129993

Back to Table of Contents

Connections